AstraZeneca Q3 Lynparza sales +42%, Farxiga sales up 32%

• AstraZeneca (NASDAQ:AZN) Q3 results:
• Revenues: $6,578M (+3%); Product Sales: $6,520M (+6%); Collaboration Revenue: $258M (-79%).
• Key product sales: Tagrisso: $1,155M (+30%); Imfinzi: $533M (+29%); Lynparza: $464M (+42%); Symbicort: $599M (-2%); Farxiga: $527M (+32%); Brilinta: $385M (-7%); Nexium: $409M (+7%); Crestor: $301M (-13%); Zoladex: $233M (+1%); Fasenra: $240M (+19%).
• Diversified growth continued across therapy areas and geographically. However, China Pulmicort COVID-19 impact reduced the development.
• Net Income: $651M (+132.5%); EPS: $0.49 (+113%); non-GAAP EPS: $0.94 (-4%).
• CF Ops: $3,001M (+88.3%)
• 2020 Guidance (at CER): Total revenue: growth increase by a high-single digit to a low-double digit percentage (unch); Core EPS: to increase by a mid- to high teens percentage (unch).
• https://seekingalpha.com/news/3631829-astrazeneca-q3-lynparza-salesplus-42-farxiga-sales-up-32-guidance-reiterated